依折麦布联合替格瑞洛治疗早发冠心病急性心肌梗死的效果

Effect of ezetimibe combined with ticagrelor in the treatment of acute myocardial infarction with early onset coronary heart disease

目的探讨依折麦布联合替格瑞洛治疗早发冠心病急性心肌梗死的有效性。方法筛选2019年7月至2021年6月本院收治的80例早发冠心病急性心肌梗死患者为研究对象,随机将其分为对照组与观察组,每组40例。对照组行常规阿司匹林+尿激酶治疗,观察组给予依折麦布+替格瑞洛治疗。比较两组的治疗效果。结果观察组的治疗总有效率高于对照组(P<0.05)。治疗后,观察组的左室射血分数(LVEF)大于对照组,左室舒张末期室间隔厚度(IVST)、左室收缩末期容积(LVESV)、左室舒张末期容积(LVEDV)、左室后壁厚度(LVPWT)小于对照组(P<0.05)。治疗后,观察组的总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)水平低于对照组,高密度脂蛋白胆固醇(HDL-C)水平高于对照组(P<0.05)。治疗后,观察组的全血低切黏度(LBV)、全血高切黏度(HBV)、血细胞比容(HCT)、血沉(ESR)水平均显著低于对照组,差异具有统计学意义(P<0.05)。结论依折麦布联合替格瑞洛治疗早发冠心病急性心肌梗死的效果显著,可促进患者的心功能恢复,降低心肌纤维化、心室重塑情况,提升循环代谢,具有重要的临床应用价值。

Objective To investigate the effectiveness of ezetimibe combined with ticagrelor in the treatment of acute myocardial infarction with early onset coronary heart disease.Methods A total of 80 patients with acute myocardial infarction with early onset coronary heart disease admitted in our hospital from July 2019 to June 2021 were selected as the study objects and randomly divided into control group and observation group,with 40 cases in each group.The control group received conventional treatment of aspirin+urokinase,and the observation group received ezetimibe+ticagrelor treatment.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the observation group was higher than that of the control group(P<0.05).After treatment,left ventricular ejection fraction(LVEF)in the observation group was greater than that in the control group,and interventricular septal thickness(IVST),left ventricular end systolic volume(LVESV),left ventricular end diastolic volume(LVEDV)and left ventricle posterior wall thickness(LVPWT)were smaller than those in the control group(P<0.05).After treatment,the levels of total cholesterol(TC),triglyceride(TG)and low-density lipoprotein cholesterol(LDL-C)in the observation group were lower than those in the control group,and the level of high-density lipoprotein cholesterol(HDL-C)was higher than that in the control group(P<0.05).After treatment,the low blood viscosity(LBV),high blood viscosity(HBV),hematocrit(HCT)and erythrocyte sedimentation rate(ESR)levels in the observation group were significantly lower than those in the control group,and the differences were statistically significant(P<0.05).Conclusion Ezetimibe combined with ticagrelor has a significant effect in the treatment of acute myocardial infarction with early onset coronary heart disease,it can promote the recovery of cardiac function,reduce myocardial fibrosis and ventricular remodeling,and enhance circulation metabolic,which has important clinical application value.